GeneCentric Licenses UNC IP for Lung Cancer Subtyping Dx, Signature Linked to anti-VEGF Rx Response | GenomeWeb

Originally published August 31.

Newly launched molecular diagnostics firm GeneCentric this week secured exclusive licenses for a lung cancer subtyping platform and a 13-gene VEGF signature from the University of North Carolina, Chapel Hill, that will enable the company to advance its first cancer diagnostic and ink partnerships with pharma.

In 2011, Charles Perou and David Neil Hayes, UNC cancer researchers who discovered molecular signatures associated with subtypes of lung cancer, founded GeneCentric with $250,000 in Series 1 funding.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.